Transcranial Photobiomodulation on Language and Cognitive Performance in Down Syndrome: A Pilot Randomized Sham-Controlled Trial
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Down syndrome (DS) is associated with persistent language and cognitive impairments and with abnormalities in cortical oscillatory activity, including in the gamma range. Transcranial photobiomodulation (tPBM) is a noninvasive neuromodulatory intervention with potential benefits for cortical physiology, language, and cognition.
Methods
We conducted a pilot randomized, double-blind, sham-controlled trial of repeated 40-Hz near-infrared tPBM in adolescents and young adults with DS. Fourteen participants were randomized 1:1 to active tPBM or sham and received 18 sessions over 6 weeks, followed by short-term and long-term follow-up. Outcomes included resting-state EEG gamma power, connected-speech measures, language and cognitive indices, and selected computerized tasks.
Results
Active tPBM did not significantly increase global resting-state EEG gamma power relative to sham at either follow-up. Pre-registered analyses did not show broad treatment benefit across outcomes, although they did identify a significant short-term advantage for active tPBM on grammatical morpheme accuracy in connected speech; in contrast, picture naming favored sham at long-term follow-up. Exploratory mechanistic analyses did not show a robust biological treatment signal. Both active and sham procedures were well tolerated, with no serious adverse events.
Conclusions
In this underpowered pilot sample, 6 weeks of 40-Hz near-infrared tPBM–delivered unilaterally, at low power, on target areas–did not demonstrate a meaningful effect size in DS. A dose-finding study for tPBM in DS, also accounting for age of participants, is recommended.
